PMID- 7946450
OWN - NLM
STAT- MEDLINE
DCOM- 19941221
LR  - 20190904
IS  - 0284-186X (Print)
IS  - 0284-186X (Linking)
VI  - 33
IP  - 6
DP  - 1994
TI  - Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and 
      somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
PG  - 693-701
AB  - Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated 
      for 4 weeks with somatostatin analog (RC-160), bombesin/gastrin releasing peptide 
      (GRP) antagonists (RC-3095 and RC-3440). In three separate experiments 
      somatostatin analog RC-160 (50 micrograms/day) released from microgranules 
      significantly reduced tumor growth. Bombesin/GRP antagonists, RC-3095 and RC-3440 
      injected subcutaneously (s.c.) twice daily at a dose of 10 micrograms had the 
      greatest and consistently significant inhibitory effect on tumor growth. RC-3095 
      given once daily s.c. at a dose of 20 micrograms was less effective. RC-3095 also 
      inhibited metastatic tumor growth after intrasplenic injection of HT-29 cells in 
      nude mice. Specific binding sites of somatostatin, bombesin and epidermal growth 
      factor (EGF) were detected on intact HT-29 cells or on the membranes from HT-29 
      tumor xenografts. The inhibitory effects of bombesin antagonists on tumor growth 
      were consistently linked with a significant down-regulation of EGF receptors. 
      Bombesin/GRP antagonists and somatostatin analogs could be considered for the 
      development of new hormonal therapies for colon cancer.
FAU - Radulovic, S
AU  - Radulovic S
AD  - Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New 
      Orleans, LA 70146.
FAU - Schally, A V
AU  - Schally AV
FAU - Reile, H
AU  - Reile H
FAU - Halmos, G
AU  - Halmos G
FAU - Szepeshazi, K
AU  - Szepeshazi K
FAU - Groot, K
AU  - Groot K
FAU - Milovanovic, S
AU  - Milovanovic S
FAU - Miller, G
AU  - Miller G
FAU - Yano, T
AU  - Yano T
LA  - eng
GR  - CA 40077/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Gastrins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 138147-78-1 (bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-)
RN  - 142824-94-0 (bombesin(6-14), Tpi(6)-Leu(13)-psi(CH2N)-Tpi(14)-)
RN  - 2PK59M9GFF (vapreotide)
RN  - 51110-01-1 (Somatostatin)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 80043-53-4 (Gastrin-Releasing Peptide)
RN  - 9002-72-6 (Growth Hormone)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PX9AZU7QPK (Bombesin)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/metabolism/secondary
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Bombesin/*analogs & derivatives/*antagonists & inhibitors/pharmacology
MH  - Colonic Neoplasms/*drug therapy/metabolism
MH  - Drug Screening Assays, Antitumor
MH  - ErbB Receptors/metabolism
MH  - Gastrin-Releasing Peptide
MH  - Gastrins/metabolism
MH  - Growth Hormone/metabolism
MH  - Humans
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Liver Neoplasms/drug therapy/secondary
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Peptide Fragments/*pharmacology
MH  - Peptides/*antagonists & inhibitors
MH  - Radioligand Assay
MH  - Somatostatin/*analogs & derivatives/therapeutic use
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.3109/02841869409121784 [doi]
PST - ppublish
SO  - Acta Oncol. 1994;33(6):693-701. doi: 10.3109/02841869409121784.